Investigation of the safety and efficacy of eszopiclone in insomnia patients
Not Applicable
- Conditions
- Insomnia
- Registration Number
- JPRN-jRCT1080222867
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 3300
Inclusion Criteria
1) insomnia patients who did not take eszopiclone before assessment
2) patients who receive assessment by using sleep questionaries
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie eszopiclone's efficacy in treating insomnia compared to benzodiazepine receptor modulators?
How does eszopiclone's safety profile in JPRN-jRCT1080222867 compare to standard-of-care hypnotics like zolpidem or zaleplon?
Are there specific biomarkers in insomnia patients that predict response to eszopiclone therapy in Eisai's observational study?
What long-term adverse events were reported in JPRN-jRCT1080222867, and how do they align with eszopiclone's pharmacokinetic properties?
How does eszopiclone's role in GABA-A receptor modulation compare to alternative insomnia treatments such as suvorexant or cognitive behavioral therapy?